NeuPath Health Announces Voting Results From the Annual General and Special Meeting of Shareholders and Issuance of Stock Options and Restricted Share Units

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 22, 2022 and the issuance of stock options and restricted share units (“RSUs”).

The results of the director elections were as follows:

Name	Votes in Favour	% Votes in Favour	Votes Withheld	% Votes Withheld
Dianne Carmichael	19,333,273	99.08%	178,750	0.92%
Jolyon Burton	19,462,023	99.74%	50,000	0.26%
Daniel Chicoine	18,934,273	97.04%	577,750	2.96%
Sasha Cucuz	18,934,273	97.04%	577,750	2.96%
Dan Legault	18,840,798	96.56%	671,225	3.44%
Grishanth Ram	18,934,273	97.04%	577,750	2.96%
Joseph Walewicz	18,934,273	97.04%	577,750	2.96%

The shareholders of the Company also voted: (i) to reappoint Ernst & Young LLP, Chartered Professional Accounts, Licensed Public Accountants, as auditors of the Company for the ensuing year; (ii) to approve the Company’s amended and restated stock option plan in the form attached as Schedule “A” to the management information circular dated May 19, 2022 prepared in connection with the Meeting, and (iii) to approve the Company’s amended and restated restricted share unit plan in the form attached as Schedule “C” to the management information circular dated May 19, 2022 prepared in connection with the Meeting.

Issuance of Stock Options and Restricted Share Units

On May 31, 2022, NeuPath granted 249,996 stock options (“Options”) to directors of the Company at an exercise price of $0.45 per share, with an expiry date of May 31, 2029. The Options are subject to time-based vesting. Options granted to directors will fully vest on May 31, 2023.

NeuPath also granted 150,000 stock options (“IR Options”) to an Investor Relations Service Provider (as such term is defined under the policies of the TSX Venture Exchange) of the Company at an exercise price of $0.70 per share, with an expiry date of May 31, 2024. The IR Options are subject to quarterly time-based vesting in accordance with the policies of the TSX Venture Exchange and will fully vest on May 31, 2023. The terms of the IR Options granted on May 31, 2022 are in accordance with the Company’s Amended and Restated Stock Option Plan initially approved by shareholders at the annual general and special meeting of shareholders held on June 23, 2020 (the “2020 AGM”).

In addition, on May 31, 2022, the Company granted 83,334 RSUs. All RSUs are subject to time-based vesting in accordance with the policies of the TSX Venture Exchange. RSUs granted to directors will fully vest on May 31, 2023. The terms of the RSUs are in accordance with the Company’s current Restricted Share Unit Plan initially approved by shareholders at the 2020 AGM.

About NeuPath

NeuPath is a vertically integrated health care provider utilizing research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by chronic pain, spinal injuries, sport-related injuries, and concussions. With equity ownership in seventeen clinics in Ontario and Alberta, NeuPath is building out a large-scale network to better serve patients across Canada and the United States. NeuPath is focused on transforming the hope of a better life into the reality of a life more fully lived.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.